Abstract: The present disclosure provides an isolated recombinant oncolytic adenovirus, a pharmaceutical composition, and uses thereof for drugs for treatment of tumors and/or cancers. The recombinant oncolytic adenovirus is a selectively replicating oncolytic adenovirus, and the genome of the recombinant oncolytic adenovirus is integrated with a coding sequence of exogenous shRNA capable of inhibiting PDL1 expression in tumor cells. The replication capability of the virus in normal primary cells is much lower than the replication capability of the virus in tumor cells. Moreover, the expressed shPDL1 can significantly reduce the level of PDL1 protein highly expressed in tumor cells. Thus, the oncolytic killing effect of the oncolytic virus and the anti-tumor immunostimulatory effect of immune cells produce a synergistic effect.

Abstract: Provided are therapeutic agent including nucleic acid and CAR-modified immune cell and the use thereof. The therapeutic agent comprises first composition and second composition, the first composition comprises a nucleic acid having a labeling polypeptide coding sequence for being introduced into a tumor cell and/or a cancer cell; the labeling polypeptide has an extracellular antigen determining region, a spacer portion, a transmembrane portion that are operatively linked, which can be expressed to form modification on the surface of the tumor cell and/or cancer cell; the extracellular antigen determining region comprises one or more epitope polypeptides; wherein, amino acid sequences of proteins on cell membrane or secreted proteins of mammal do not comprise the epitope polypeptide amino acid sequence in the natural state; the second composition comprises chimeric antigen receptor modified immune cell which specifically recognize and bind to the extracellular antigen determining region.

Abstract: Provided are therapeutic agent including nucleic acid and CAR-modified immune cell and the use thereof. The therapeutic agent comprises first composition and second composition, the first composition comprises a nucleic acid having a labeling polypeptide coding sequence for being introduced into a tumor cell and/or a cancer cell; the labeling polypeptide has an extracellular antigen determining region, a spacer portion, and a transmembrane portion that are operatively linked, which can be expressed to form modification on the surface of the tumor cell and/or cancer cell; the extracellular antigen determining region comprises one or more epitope polypeptides; wherein, amino acid sequences of proteins on cell membrane or secreted proteins of mammal do not comprise the epitope polypeptide amino acid sequence in the natural state; the second composition comprises chimeric antigen receptor modified immune cell which specifically recognize and bind to the extracellular antigen determining region.

Abstract: The present disclosure provides an isolated recombinant oncolytic adenovirus, a pharmaceutical composition, and uses thereof for drugs for treatment of tumors and/or cancers. The recombinant oncolytic adenovirus is a selectively replicating oncolytic adenovirus, and the genome of the recombinant oncolytic adenovirus is integrated with a coding sequence of exogenous shRNA capable of inhibiting PDL1 expression in tumor cells. The replication capability of the virus in normal primary cells is much lower than the replication capability of the virus in tumor cells. Moreover, the expressed shPDL1 can significantly reduce the level of PDL1 protein highly expressed in tumor cells. Thus, the oncolytic killing effect of the oncolytic virus and the anti-tumor immunostimulatory effect of immune cells produce a synergistic effect.

Abstract: The present disclosure provides an isolated recombinant oncolytic adenovirus, a pharmaceutical composition, and uses thereof for drugs for treatment of tumors and/or cancers. The recombinant oncolytic adenovirus is a selectively replicating oncolytic adenovirus, and the genome of the recombinant oncolytic adenovirus is integrated with a coding sequence of exogenous shRNA capable of inhibiting PDL1 expression in tumor cells. The replication capability of the virus in normal primary cells is much lower than the replication capability of the virus in tumor cells. Moreover, the expressed shPDL1 can significantly reduce the level of PDL1 protein highly expressed in tumor cells. Thus, the oncolytic killing effect of the oncolytic virus and the anti-tumor immunostimulatory effect of immune cells produce a synergistic effect.

Abstract: Provided are therapeutic agent including nucleic acid and CAR-modified immune cell and the use thereof. The therapeutic agent comprises first composition and second composition, the first composition comprises a nucleic acid having a labeling polypeptide coding sequence for being introduced into a tumor cell and/or a cancer cell; the labeling polypeptide has an extracellular antigen determining region, a spacer portion, and a transmembrane portion that are operatively linked, which can be expressed to form modification on the surface of the tumor cell and/or cancer cell; the extracellular antigen determining region comprises one or more epitope polypeptides; wherein, amino acid sequences of proteins on cell membrane or secreted proteins of mammal do not comprise the epitope polypeptide amino acid sequence in the natural state; the second composition comprises chimeric antigen receptor modified immune cell which specifically recognize and bind to the extracellular antigen determining region.

Abstract: Provided are an isolated recombinant oncolytic poxvirus capable of being regulated and controlled by microRNA and a use thereof. The isolated recombinant oncolytic poxvirus can be regulated and controlled by microRNA, and the expression level of the microRNA in tumor cells of a mammal is lower than that in normal cells of the same mammal. A target sequence of the microRNA is integrated in a 3?UTR region of an E10R gene in a recombinant oncolytic poxvirus genome.

Abstract: The invention provides an isolated recombinant oncolytic vaccinia virus, pharmaceutical compositions and uses thereof for drugs for treatment of tumors and/or cancers. The isolated recombinant oncolytic vaccinia virus is functionally deficient in the TK gene and the VGF gene, and the genome of the recombinant oncolytic vaccinia virus is integrated with an exogenous IL-21 gene, and wherein the IL-21 gene is capable of being expressed in tumor cells. The recombinant oncolytic vaccinia virus can selectively replicate in tumor cells, and can also fully exert the anti-tumor immune effect of the exogenous IL-21, such that the oncolytic killing effect of the oncolytic virus and the anti-tumor immune stimulation effect of IL-21 achieve a synergic effect.

Abstract: The present disclosure provides an isolated recombinant oncolytic adenovirus, a pharmaceutical composition, and uses thereof for drugs for treatment of tumors and/or cancers. The recombinant oncolytic adenovirus is a selectively replicating oncolytic adenovirus, and the genome of the recombinant oncolytic adenovirus is integrated with a coding sequence of exogenous shRNA capable of inhibiting PDL1 expression in tumor cells. The replication capability of the virus in normal primary cells is much lower than the replication capability of the virus in tumor cells. Moreover, the expressed shPDL1 can significantly reduce the level of PDL1 protein highly expressed in tumor cells. Thus, the oncolytic killing effect of the oncolytic virus and the anti-tumor immunostimulatory effect of immune cells produce a synergistic effect.

Abstract: Techniques reduce data recovery time of a storage system. The techniques involve: determining a plurality of service layers associated with a data recovery process of the storage system, the plurality of service layers being obtained by partitioning a plurality of services related to the data recovery process based on a data recovery order; in response to a start of data recovery in a target service layer among the plurality of service layers, determining, from at least one service layer lower than the target service layer among the plurality of service layers, at least one service unrelated to the data recovery in the target service layer; and disabling the determined service. With such techniques, unnecessary services in lower layers can be disabled during the data recovery process, and thereby the data recovery time may be reduced.

Abstract: Techniques reduce data recovery time of a storage system. The techniques involve: determining a plurality of service layers associated with a data recovery process of the storage system, the plurality of service layers being obtained by partitioning a plurality of services related to the data recovery process based on a data recovery order; in response to a start of data recovery in a target service layer among the plurality of service layers, determining, from at least one service layer lower than the target service layer among the plurality of service layers, at least one service unrelated to the data recovery in the target service layer; and disabling the determined service. With such techniques, unnecessary services in lower layers can be disabled during the data recovery process, and thereby the data recovery time may be reduced.

Abstract: A system and method for wireless wide area network (WWAN) assisted proximity wireless local area network (WLAN) peer-to-peer (P2P) connection and offloading is disclosed. The method includes the operation of identifying a first wireless device and a second wireless device between which a WLAN P2P connection is desired. Each wireless device can have a WWAN radio and a WLAN radio. WLAN information can be sent for at least one of the first and second wireless devices via the WWAN to a P2P configuration server. A WLAN P2P configuration can be received from the P2P configuration server at the first and second wireless devices via the WWAN for WLAN P2P communication between the first and second wireless devices. A WLAN P2P connection can be set up between the first and second wireless devices using the WLAN P2P configuration. The first and the second wireless devices can communicate using the WLAN P2P connection.

Abstract: A grounding grid breakpoint diagnostic method for a transient electromagnetic method, based on a transient electromagnetic detection apparatus. The method comprises: (101) disposing a test line at a position above a grounding grid to be diagnosed on the ground, and determining coordinates of a detection point; (102) obtaining information about coordinates of the detection point, and coinciding the center of the transient electromagnetic detection apparatus with the coordinates of the detection point; (103) performing, by the transient electromagnetic detection apparatus, measurement along the test line point by point, so as to obtain measurement data; (104) processing, by using diagram forming software, the measurement data to form a longitudinal resistivity cross-section diagram of the detection point according to a preset formula; (105) determining whether a breakpoint occurs at the detection point according to the longitudinal resistivity cross-section diagram.

Abstract: A method and apparatus for wireless location tracking by a wireless device. In one embodiment of the invention, the wireless device has logic to determine the information of a plurality of specific location points and to determine the location of the wireless device based on the information of the plurality of specific location points. The specific location points are selected from a target area where the wireless device is located. By selecting the specific location points in the target area, it allows hidden Access Points (APs) or Base Stations (BSs) to be detected and measured and it increases the accuracy of the tracking of the wireless device.

Abstract: The present application provides a method and a system for detecting data of an instrument.

Abstract: A user equipment (UE) is arranged to send an uplink power reference signal to an enhanced Node B (eNB) associated with multiple reception points (RPs), to receive identification of an RP set and a downlink reference signal power level, to determine a path loss estimate for each downlink reference signal received from RPs of the RP set, to determine an uplink power level that is a function of the path loss estimates determined for the downlink signals received from the RPs of the RP set, and to use the determined uplink power level during communication with the multiple RPs.

Abstract: A grounding grid breakpoint diagnostic method for a transient electromagnetic method, based on a transient electromagnetic detection apparatus. The method comprises: (101) disposing a test line at a position above a grounding grid to be diagnosed on the ground, and determining coordinates of a detection point; (102) obtaining information about coordinates of the detection point, and coinciding the center of the transient electromagnetic detection apparatus with the coordinates of the detection point; (103) performing, by the transient electromagnetic detection apparatus, measurement along the test line point by point, so as to obtain measurement data; (104) processing, by using diagram forming software, the measurement data to form a longitudinal resistivity cross-section diagram of the detection point according to a preset formula; (105) determining whether a breakpoint occurs at the detection point according to the longitudinal resistivity cross-section diagram.

Abstract: Uplink power control in a macro cell in a wireless network comprises transmitting a reference signal from a base station device to at least one wireless device within the macro cell. The macro cell comprises the base station device and at least one radio transmitter device that is communicatively coupled to and remote from the base station device. The base station device and one or more radio transmitter devices could be selected to be a transmission point, a reception point or a combination thereof, for each wireless device. Information relating to a transmission power of the base station device is also transmitted to the at least one wireless device. An uplink signal is received from the at least one wireless device containing information relating to an uplink power determination that is based on the reference signal and the information relating to the transmission power of the base station device.

Abstract: In accordance with some embodiments, spatial and temporal locality between threads executing on graphics processing units may be analyzed and tracked in order to improve performance. In some applications where a large number of threads are executed and those threads use common resources such as common data, affinity tracking may be used to improve performance by reducing the cache miss rate and to more effectively use relatively small-sized caches.

Abstract: A user equipment (UE) is arranged to send an uplink power reference signal to an enhanced Node B (eNB) associated with multiple reception points (RPs), to receive identification of an RP set and a downlink reference signal power level, to determine a path loss estimate for each downlink reference signal received from RPs of the RP set, to determine an uplink power level that is a function of the path loss estimates determined for the downlink signals received from the RPs of the RP set, and to use the determined uplink power level during communication with the multiple RPs.